Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis.

Background and Objective: A double-blind phase 3 study was conducted to compare posaconazole 300 mg intravenously (IV)/300 mg orally once daily (twice daily day 1) with voriconazole 4 mg/kg IV twice daily/200 mg orally twice daily (6 mg/kg day 1) for treatment of invasive aspergillosis. This analysis was conducted to summarize the pharmacokinetics and exposure-response relationships of posaconazole and voriconazole using plasma trough concentration (C _trough ) as a surrogate for exposure from the double-blind phase 3 study.
Methods: The pharmacokinetic evaluable population included all intention-to-treat (ITT) participants with at least one plasma concentration during the treatment period. Treatment blinding was maintained without therapeutic drug monitoring. C _trough sampling occurred throughout treatment; efficacy and safety were evaluated using quartiles determined by mean C _trough concentrations. Exposure efficacy variables included day 42 all-cause mortality (primary study endpoint) and global clinical response. Exposure safety variables included all adverse events and treatment-related adverse events.
Results: The pharmacokinetic analysis population included 506 of 575 ITT participants (437 with C _trough concentrations: 228 posaconazole, 209 voriconazole). No trend was seen across quartiles of posaconazole C _trough for the key efficacy endpoint of all-cause mortality through day 42. Participants in the highest quartile of voriconazole C _trough had higher all-cause mortality through day 42 than participants in the lower three quartiles of voriconazole C _trough . Similar findings were observed for global clinical response and C _trough . No clear exposure safety trend by quartile was seen for posaconazole or voriconazole.
Conclusions: A strong exposure-response relationship was not observed across the range of exposure from the administered doses and formulations for posaconazole or voriconazole.
Trial Registration: NCT01782131; registered January 30, 2013.
(© 2023. The Author(s).)